Related Experiment Video
Updated: Jun 12, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus
Marina C Garassino1,2, Ying Cheng3, Delvys Rodriguez-Abreu4
1Department of Medicine, University of Chicago, Chicago, IL, USA. mgarassino@medicine.bsd.uchicago.edu.
Introduction:
Response Evaluation Criteria in Solid Tumors (RECIST) is the primary tool for assessing tumor response in solid tumors. Immunotherapy elicits unique response patterns, and assessment of their contribution to overall survival (OS) is of interest. We evaluated tumor size changes (TSC) for association with OS, evaluated whether deeper response had greater association with OS than the 30% RECIST cutoff, and quantified the contribution of objective response rate (ORR) and duration of response (DOR) to OS benefit using data from KEYNOTE-189 and KEYNOTE-407 examining first-line pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer (NSCLC).
Methods:
Associations between early TSC (percentage change from baseline in sum of target lesion diameters) and OS were evaluated using recursive partitioning analyses, C-index, and time-varying receiver operating characteristic curve. Deeper response and OS associations were assessed in sensitivity analyses. Contribution of TSC, ORR, and DOR to the OS benefit of pembrolizumab plus chemotherapy (versus chemotherapy) was quantified with a proportion of treatment effect analysis. Data cutoff was May 2019.
Results:
In total, 1175 participants were included (KEYNOTE-189, n = 616; KEYNOTE-407, n = 559). At week 12, -30% TSC had a greater association with OS than other cutoffs, which was similar to week 12 ORR. Deeper response did not have greater association with OS than the 30% RECIST cutoff. For pembrolizumab plus chemotherapy versus chemotherapy in KEYNOTE-189, the proportion of treatment effect on OS benefit for DOR coupled with ORR was higher than ORR alone (0.57 versus 0.36) or an alternative TSC cutoff (0.57 versus 0.08 for -10%, 0.09 for -20%, and 0.20 for -30%), with similar results in KEYNOTE-407 for DOR and ORR versus ORR alone (0.92 versus 0.61) or an alternative TSC cutoff (0.92 versus 0.36, 0.43, and 0.40, respectively).
Conclusions:
These ad hoc exploratory analyses suggest that RECIST remains a valid assessment for metastatic NSCLC treated with immunotherapy plus chemotherapy. Early responses per RECIST criteria predicted improved OS.
Trial Registration:
ClinicalTrials.gov, NCT02578680, NCT02775435.
More Related Videos
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Related Concept Videos
01:21Cancer Survival Analysis
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...